Addex Therapeutics Ltd. (ADXN) — Institutional Holders, Q2 2026
2 institutional investment managers reported a ADXN position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $274.00. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ADXN in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- UBS Group AGNew · +47 sh+$282.00
Biggest sellers
- MORGAN STANLEYSold out · -301 sh-$1.8K
- GAMMA InvestingSold out · -81 sh-$486.00
- RHUMBLINE ADVISERSSold out · -72 sh-$432.00
ADXN 13F holders ranked 1–2 of 2
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | UBS Group AG#1 · 47 sh | 47 | $268.00 | 0.00% | New |
| 2 | SBI Securities , Ltd.#2 · 1 sh | 1 | $6.00 | — | 0.0% |
Funds that sold out of ADXN in Q2 2026 (3)
Held ADXN at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| MORGAN STANLEY301 sh | 301 | $1.9K |
| GAMMA Investing81 sh | 81 | $509.00 |
| RHUMBLINE ADVISERS72 sh | 72 | $450.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.